Markets
Leaderboard
Will Brazil have any new genetic or cellular therapy products registered at ANVISA by the end of 2021? No: real money —, play money 67% Yes: real money —, play money 33% Volume: real money 1040, play money 1394.81 Bettors: real money 0, play money 7 Categories: Science, Genetics Related markets Will the US, UK or EU approve a gene editing therapy for a new condition during 2026? (ID: 239427) Volume: real 37.10543526, play 8014.42660966 Bettors: real 4, play 6 Leading (real money): Will the US, UK or EU approve a gene editing therapy for a new condition during 2026? 20% Leading (play money): Will the US, UK or EU approve a gene editing therapy for a new condition during 2026? 35% Extinct mammoth hybrids to be born alive by the end of 2027? (ID: 209130) Volume: real 67.78509857, play 11414.67183885 Bettors: real 11, play 28 Leading (real money): Extinct mammoth hybrids to be born alive by the end of 2027? 42% Leading (play money): Extinct mammoth hybrids to be born alive by the end of 2027? 15% Will the Dodo bird be de-extinct by the end of 2028? (ID: 217201) Volume: real 57.05983354, play 4175.09899414 Bettors: real 6, play 17 Leading (real money): Will the Dodo bird be de-extinct by the end of 2028? 7% Leading (play money): Will the Dodo bird be de-extinct by the end of 2028? 16%

Will Brazil have any new genetic or cellular therapy products registered at ANVISA by the end of 2021?

Market Rules

On February 18th, 2020, the Brazilian Health Agency, ANVISA, approved the rules for the registration of new advanced therapy products. Such definition includes products related to therapies that modify the patient's DNA and the use of modified cells to fight cancer, for example.

Before the approval of these rules, only clinical trials were possible in the country - by February 2020 eight such clinical trials were being monitored, and three more were under analysis. With the approval, however, Brazil now has the necessary regulatory bases to develop and register high-tech products based on human cells and genes, becoming a reference in Latin America.

If by December 31st, 2021, any new advanced therapy product - be it based on genetic or cellular therapy - is registered at ANVISA, this question will be resolved as "Yes"

People also viewed